GlassScriptPhysician profile
Mohammad I Qureshi
NPI 1982684254
$33,211.84
in general payments reported to CMS, 2019-2025
48 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,859 · 2021: $2,181 · 2022: $3,078 · 2023: $3,361 · 2024: $7,375 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $3,210 · Education: $60.66 · Travel and Lodging: $55.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,746.81 |
| Consulting Fee | $3,210.00 |
| Education | $60.66 |
| Travel and Lodging | $55.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,204.15 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $3,265.20 | 2024 | |
| Abbott Laboratories | $2,529.61 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Gallant |
| Amgen INC. | $1,836.16 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,606.25 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,533.16 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $994.50 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $927.37 | 2021-2025 | Mounjaro, Zepbound |
| Kestra Medical Technology Services, INC. | $916.97 | 2022-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $912.05 | 2020-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $884.68 | 2021-2025 | Verquvo, Capvaxive |
| Medical Device Business Services, INC. | $836.97 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $708.70 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $669.06 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Artivion, INC. | $587.77 | 2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $505.41 | 2020-2025 | Nexletol |
| Scpharmaceuticals INC. | $245.59 | 2023-2025 | |
| Chiesi USA, INC. | $224.90 | 2020-2025 | Kengreal |
| Medtronic Vascular, INC. | $216.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.57 | 2024-2025 | |
| Medtronic, INC. | $172.86 | 2023-2024 | Hawkone, In.Pact Admiral |
| Abiomed | $169.50 | 2020-2024 | Impella |
| Inari Medical, INC. | $158.42 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bard Peripheral Vascular, INC. | $156.30 | 2019-2021 | |
| Genzyme Corporation | $149.99 | 2022 | |
| Penumbra, INC. | $142.57 | 2024 | Penumbra System |
| Impulse Dynamics (USA) INC. | $122.20 | 2024 | Optimizer |
| Inspire Medical Systems, INC. | $119.78 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $119.61 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $118.72 | 2024 | Arcalyst |
| Philips North America LLC | $110.56 | 2023 | |
| Astellas Pharma US INC | $99.99 | 2020 | |
| Pfizer INC. | $80.65 | 2019-2022 | |
| Axogen | $78.26 | 2020 | |
| Opsens INC. | $76.71 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $71.69 | 2021 | |
| Bridgebio Pharma, INC. | $69.11 | 2025 | Attruby |
| Daiichi Sankyo INC. | $58.36 | 2021-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $50.74 | 2019 | |
| Arbor Pharmaceuticals, INC. | $47.75 | 2021 | |
| Edwards Lifesciences Corporation | $46.25 | 2019-2022 | |
| Irhythm Technologies, INC. | $46.02 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $45.83 | 2022-2023 | |
| Preventice Services, LLC | $25.86 | 2019 | |
| Azurity Pharmaceuticals, INC. | $21.46 | 2023 | Edarbi |
| Teleflex LLC | $17.06 | 2023 | Manta |
| Vivaquant INC, Dba Rhythm Express | $12.37 | 2025 | Rhythm Express |
| Amarin Pharma, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.